Related Experiment Video
Updated: Aug 13, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
[New thrombolytic agents in myocardial infarction]
B Charbonnier1, M Lang, M Brochier
1Clinique cardiologique, CHU Trousseau, Tours.
Newer thrombolytic drugs, including recombinant tissue plasminogen activator (rt-PA) and recombinant single-chain urokinase plasminogen activator (r-scu-PA), show improved efficacy and reduced bleeding risk compared to older agents like streptokinase (SK) and urokinase (UK) for treating acute myocardial infarction.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiology
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

